Posted on 1/7/21
bluebird bio Inc., Undervalued Acquisition Candidate
SummaryI estimate the fair value for BLUE between $5-7 billion based on similar acquisitions.2021 could be an inflection point with the anticipated approval of the company's . . .
Posted on 6/23/20
Own Biogen For Long-Term Safety And Growth
SummaryBiogen is the neuroscience market leader and continues making investments to maintain that lead.Neurological disease treatments represent the largest unmet need in the medical industry with . . .
Boston
